Researchers test cutting treatment time in half for eye disease
NCT ID NCT07308964
Summary
This study aims to see if a shorter treatment course works as well as the standard one for thyroid eye disease. It will compare 4 infusions versus 8 infusions of the drug Teprotumumab (Tepezza). The trial is for patients who show a good response early in their treatment. The goal is to determine if the shorter regimen is equally effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.